Indian CEOs On Plugging Quality Gaps: Yes We Can

The top bosses of six leading Indian firms were unequivocal that there is room for improvement on the quality front at a recent conference in Mumbai, but they also emphasized senior management engagement and resolve to get a "quality movement" going in their respective firms and in the domestic industry, in general.

The head honchos of Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd., Cipla Ltd., Lupin Ltd. and Zydus Cadila sat through day-long sessions at the India Pharmaceutical Forum 2016, where officials from the US FDA, MHRA and the EMA identified critical issues around quality challenges.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Focus On Asia

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By 

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

Novotech CEO On Flexible Trial Solutions Amid Tariff, Geopolitical Tensions

 

Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.